Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab

Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron's casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news